Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma CDMO offers integrated end-to-end solutions for development & commercialization of intermediates & APIs for small molecules.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    veranova-m-2025-06-30

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Acino

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    $ API Ref.Price (USD/KG) : 97,339Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    UCB's Fintepla shows potential to treat a 3rd epilepsy disorder
    UCB's Fintepla shows potential to treat a 3rd epilepsy disorder

    28 Jun 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/ucbs-fintepla-shows-potential-expand-3rd-epilepsy-indication

    FIERCE PHARMA
    28 Jun 2025
    Share Share
    UCB Reports Positive Ph3 GEMZ Results in CDKL5 Disorder
    UCB Reports Positive Ph3 GEMZ Results in CDKL5 Disorder

    27 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ucb-announces-positive-results-from-gemz-phase-3-study-of-fenfluramine-in-cdkl5-deficiency-disorder-302492480.html

    PR NEWSWIRE
    27 Jun 2025
    Share Share
    Epilepsia Publishes FINTEPLA Long-Term Safety Data In Dravet
    Epilepsia Publishes FINTEPLA Long-Term Safety Data In Dravet

    12 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/epilepsia-publishes-final-analysis-of-open-label-extension-study-of-long-term-safety-and-effectiveness-of-fintepla-fenfluramine-in-children-and-adults-with-dravet-syndrome-302400217.html

    PR NEWSWIRE
    12 Mar 2025
    Share Share
    FINTEPLA® (Fenfluramine) Results On Managing Seizures Published In Epilepsia
    FINTEPLA® (Fenfluramine) Results On Managing Seizures Published In Epilepsia

    24 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fintepla-fenfluramine-results-examining-its-impact-in-managing-generalized-tonic-clonic-seizures-in-developmental-and-epileptic-encephalopathies-published-in-epilepsia-302179742.html

    PR NEWSWIRE
    24 Jun 2024
    Share Share
    UCB Launches Dravet Syndrome Sound of Profound Moments: Family Video Project
    UCB Launches Dravet Syndrome Sound of Profound Moments: Family Video Project

    20 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240617167454/en

    BUSINESSWIRE
    20 Jun 2024
    Share Share
    Acino completes acquisition of M8 Pharmaceuticals
    Acino completes acquisition of M8 Pharmaceuticals

    04 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/04/2789958/0/en/Acino-completes-acquisition-of-M8-Pharmaceuticals-significantly-expanding-presence-and-capabilities-in-Latin-America.html

    GLOBENEWSWIRE
    04 Dec 2023
    Share Share